🔥 Wednesday 20 August 2025 Wed, 20 Aug 2025

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Astron Corporation Limited is set to redomicile from Hong Kong to Australia through a scheme of arrangement, creating a new Australian parent company, Aus NewCo. This move aims to align the corporate structure with its Australian assets and simplify shareholder voting.

Euroz Hartleys Group Limited reported a robust 87.7% increase in net profit for FY25, driven by growth across brokerage, underwriting, and wealth management. The company declared a fully franked full-year dividend of 5.5 cents per share, reflecting confidence in its operational leverage and balance sheet strength.

Alliance Aviation Services reported a robust 19% revenue increase to $769.7 million in FY25, driven by fleet expansion and strong operational performance. The company’s strategic investments and contract growth set a positive tone for FY26.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Alliance Aviation Services Limited reported a 19% revenue increase to $760.9 million in FY2025, while net profit after tax slipped 5% to $57.3 million amid operational challenges. The company declared a fully franked dividend of 3.0 cents per share and expanded its fleet to 79 aircraft.

Harmoney has delivered a robust FY25 performance, exceeding its upgraded profit guidance with strong loan book growth and improved efficiency. The fintech lender projects a remarkable 111% increase in cash NPAT for FY26, driven by its AI-powered Stellare 2.0 platform and strategic expansion plans.

Harmoney Corp has delivered a record FY25 performance, exceeding profit expectations and boosting its FY26 profit forecast by 20%, driven by strong loan growth and its advanced Stellare 2.0 platform.

Ideagen has completed its acquisition of Envirosuite through a scheme of arrangement, with shareholders receiving A$0.09 per share. Envirosuite shares will be officially delisted from the ASX on 21 August 2025.

Universal Biosensors Pty Limited has entered voluntary administration with KPMG appointed as administrators, signaling urgent financial distress and a potential restructuring ahead.

Astron Corporation has completed its redomicile from Hong Kong to Australia, launching Astron Limited (Aus NewCo) as the new ASX-listed parent company with a 2-for-1 share consolidation.

Straker Ltd reported a 10% revenue decline in FY25 but achieved record gross margins and adjusted EBITDA, underscoring its strategic shift to AI-driven language services and expanding IBM partnership.

Iris Cairns Property Pty Ltd has increased its cash takeover offer for Reef Casino Trust units to A$3.72 per unit, with the Reef Corporate Services Limited board unanimously recommending acceptance. The offer values the trust at approximately A$185.3 million and awaits regulatory approvals.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

LDR Assets Pty Ltd, part of the Lederer Family Office, has initiated an off-market takeover offer for all stapled securities in the Elanor Commercial Property Fund at a 5.3% premium to recent prices. The bid signals a potential overhaul of ECF’s management and governance.

Ainsworth Game Technology reported a steady half-year profit of $4.9 million on a 25% revenue increase, driven by strong domestic sales and new product launches, while navigating regional challenges and a looming Novomatic takeover bid.

Redcastle Resources Limited has resumed trading on the ASX following key announcements about a joint venture farm-out, a strategic placement, and a major gold project acquisition.

Redcastle Resources has partnered with BML Ventures to fast-track gold production at key deposits while massively expanding its Eastern Goldfields footprint through a strategic tenement acquisition.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

WOTSO’s FY25 results reveal a robust 14% increase in underlying EBITDA, driven by its expanding flexible workspace portfolio now spanning 31 locations. Strategic investments and partnerships underpin a confident outlook toward $58 million revenue by FY30.

Frontier Digital Ventures has uncovered apparent misappropriation of approximately USD 430,000 within its Colombian business, Fincaraiz, prompting an ongoing investigation and operational safeguards.

Vicinity Centres reported a robust FY25 with statutory net profit surging to $1 billion, driven by strategic portfolio repositioning and strong retail sales growth. The company’s focus on premium assets and disciplined capital management sets the stage for continued growth in FY26.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.